RE:RE:RE:RE:RE:RE:RE:RE:RE:$3.50Marsolais said that what they see in the phase Ia is in line with what they saw in the preclinical experiments and in preclinical they achieved three times the MTD of docetaxel alone. One thing we don't know about this patient with neutropenia at 420 mg/m2 is if he has a cancer overexpressing sortilin or not. I still think that toxicity will happen at lower doses on patients with a cancer not overexpressing sortilin. Remember, they said FDA ask for all comers to clarify the role of overexpression. All that to say that the three times MTD achieved in preclinical work was on mice with xenograft tumors overexpressing sortilin. So the "in line" with preclinical that Marsolais alluded to can still make sense. All that being said, they were well behind schedule being only at one patient treated at 420 mg/m2. So I don't know when they will reach the MTD and the end of this phase Ia. They already said that it could go until the begining of 2022.
Wino115 wrote: We know at the quarterly they had at least one at the 420 level, where they mentioned the SAE2 neutropenia (non febrile) and that they continued dosing one other at that level at least. I think the protocol would have been to figure out the issues with that one patient but to have 3 at that level of 420. Then if nothing comes up, wasn't there one more level to try and then that woudl be the ultimate max they were going to trial. I'd have to pull out that slide, but I think the max was something in the 700 range. So they may actually be getting to that level now, or finishing up on the 420 and making that the RP2D.
scarlet1967 wrote: Why would they start printing shares at "ridiculously low share price". I certainly hope the board members have the courage to wait this time round before pulling the trigger. The oncology results at this stage with or without efficacy are statically not enough to based their decision on although good results are encouraging going into phase1b basket trial. The trial still ongoing so no SAE3 or more(significant adverse effects), they were at 420mg/m2 last time they reported which could mean a large intracellular concentration of docetaxel, they keep hiring scientists as per their LinkedIn page they are now down from 8 positions to 4, they seems to be attending AASLD and the presentation at the Credit Suisse etc. point is it's too early too cheaply to sell and panicking now like they did in January( market crash) is premature so if anyone at the company is paying attention don't contradict yourself by selling at per yourself low prices. Instead get out there in front of your retail and institutional investors sell yourself your visions and the mission.